Ezra Pharmaceutical, Inc.
Innovative solutions to diabetes.
Ezra Pharmaceutical, Inc. is dedicated to developing novel preventative therapeutics for diabetic complications.
Diabetes is a chronic disease that affects almost 30 million Americans and 270 million people worldwide, statistics that are expected to double within the next 25 years, according to the American Diabetes Association. Despite great strides made in the management of this disease, a great unmet clinical need exists for preventative therapies for diabetic retinopathy, nephropathy and vascular complications.
Ezra Pharmaceutical, Inc. is taking advantage of recent biomedical breakthroughs and leveraging global connections to bring to market innovative therapeutics for diabetic complications with the hope of changing the paradigm of diabetes management.
Diabetes is a chronic disease that affects almost 30 million Americans and 270 million people worldwide, statistics that are expected to double within the next 25 years, according to the American Diabetes Association. Despite great strides made in the management of this disease, a great unmet clinical need exists for preventative therapies for diabetic retinopathy, nephropathy and vascular complications.
Ezra Pharmaceutical, Inc. is taking advantage of recent biomedical breakthroughs and leveraging global connections to bring to market innovative therapeutics for diabetic complications with the hope of changing the paradigm of diabetes management.
For further information, contact us at: ceo@ezrapharmaceutical.com